Biomarker Testing And Targeted Therapy Use Among Patients With Non–Small Cell Lung Cancer (NSCLC) In The United States: An Analysis Using A Physician Notes Real-World Database 

This poster was originally presented at the ASCO Annual Meeting 2024, held May 31–June 4, 2024, in Chicago, IL.

Authors: Vernon Videña, PharmD, Dave Iwanyckyj, Fernando Otalora, Melanie Jardim, PhD 

Affiliations: Amplity, Langhorne, PA, USA 

Introduction 

This study leveraged AnswerY™ (formerly known as Amplity Insights), our robust, HIPAA-compliant real-world database (RWD) composed of transcribed physician notes, to analyze patterns of biomarker testing + subsequent use of targeted therapies in U.S. patients with NSCLC.  

Methods  

• >60 million electronic medical transcription records from AnswerY RWD were analyzed from nearly 120,000 healthcare providers at ~40,000 inpatient/outpatient care sites across 50 states and 2 U.S. territories 
• Patient records from the database were included in the analysis if they had a confirmed diagnosis of NSCLC  
• Patient characteristics, biomarker testing and results, and treatment use were summarized and described 

Results 

• Biomarker testing is underutilized and may not be conducted as recommended by current guidelines

• Among patients with confirmed actionable mutations, many are not receiving the appropriately targeted therapy  

Conclusion  

• This analysis highlights that many patients with NSCLC may not be benefiting from treatment with precision therapies, suggesting that there is an urgent need for additional educational strategies to optimize the adoption of precision oncology + elevate patient outcomes 

DOWNLOAD POSTER